Amylase-producing IgD-type multiple myeloma

• Published in: Journal of internal medicine Vol. 232; no. 5; p. 457
• Main Authors: Delannoy, A, Hamels, J, Mecucci, C, Fally, P, Wallef, G, de Fooz, C, Carlier, B
• Format: Journal Article
• Language: English
• Published: England 01-11-1992
• Subjects: Adrenal Cortex Hormones - administration & dosage; Adrenal Cortex Hormones - therapeutic use; Amylases - blood; Amylases - chemistry; Bone Marrow Examination; Chromosome Aberrations - diagnosis; Chromosome Aberrations - genetics; Chromosome Disorders; Chromosomes, Human, Pair 1; Cyclophosphamide - administration & dosage; Cyclophosphamide - therapeutic use; Drug Therapy, Combination; Electrophoresis, Agar Gel; European Continental Ancestry Group; Female; Gene Deletion; Gene Rearrangement; Humans; Immunoenzyme Techniques; Immunoglobulin D - blood; Karyotyping; Middle Aged; Multiple Myeloma - complications; Multiple Myeloma - diagnosis; Multiple Myeloma - drug therapy; Plasma Cells - chemistry; Renal Dialysis
• ISSN: 0954-6820
• DOI: 10.1111/j.1365-2796.1992.tb00615.x

We describe the case of a 63-year-old woman with an IgD-type multiple myeloma and hyperamylasaemia. The evolution of the amylase concentration, the immunohistochemical data and the intracellular amylase contents of the plasma cell were consistent with secretion of amylase by the malignant clone. Moreover, cytogenetic analysis of the bone marrow revealed two structural rearrangements involving chromosome 1 near the amylase locus. Multiple myeloma should be added to the amylase-secreting tumours. This rare entity is not confined to Japan, where it was first recognized.